CRSP·Nasdaq·US

CRISPR Therapeutics

CRISPR Therapeutics is a biopharmaceutical company focused on developing CRISPR-based therapeutics using CRISPR/Cas9 technology, with a portfolio spanning hemoglobinopathies, in vivo, CAR T, and regenerative medicine franchises. It developed CASGEVY, the first approved CRISPR-based gene-editing therapy, in collaboration with Vertex Pharmaceuticals for patients with sickle cell disease and transfusion-dependent beta thalassemia.

Source: SEC 10-K Feb 12, 2026

Create free account

Recent Activity

Updated Oct 24, 2026

–CRISPR Therapeutics announced on October 19, 2026 a Chief Financial Officer transition involving its current CFO, Raju Prasad.

Past updates are part of the Pro plan.

Thematic Position

CRSP

Healthcare Innovation

Cell TherapyLeader

Gene Therapy & EditingLeader

Relationship Groups

Suppliers2

Partners7

Licensing5

Competitors28

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

9 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

sanctionarmed conflicttariffpolitical instability

Geopolitical tensions and sanctions on Russia disrupt global operations and capital access

SEC 10-KFeb 12, 2026

The full regulatory passage is part of the Pro plan.

10 more · Regulatory and geopolitical insights are part of the Pro plan.